Form 4: RIKER LAUREN reports acquisition/exercise transactions in PCRX

Rhea-AI Filing Summary

RIKER LAUREN reported acquisition or exercise transactions in a Form 4 filing for PCRX. The filing lists transactions totaling 19,273 shares. Following the reported transactions, holdings were 71,586 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIKER LAUREN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		19,273(1)	A	$0	71,586.242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Lauren Riker?

Pacira BioSciences reported an equity grant to Senior Vice President, Finance Lauren Riker of 19,273 restricted stock units of common stock at $0 per share. This was a compensation award, not an open-market stock purchase or sale, and increased her direct beneficial holdings.

How many Pacira (PCRX) shares does Lauren Riker own after this Form 4 filing?

After the reported grant, Lauren Riker beneficially owns 71,586.242 shares of Pacira common stock directly. This total includes the 19,273 restricted stock units awarded on February 11, 2026, as disclosed in the Form 4 insider transaction report.

Was the Pacira (PCRX) insider transaction a stock purchase or an RSU grant?

The transaction was a grant of restricted stock units (RSUs), not a cash stock purchase. Lauren Riker received 19,273 RSUs of Pacira common stock at $0 per share as part of her compensation, classified as a grant, award, or other acquisition.

What are the vesting terms of Lauren Riker’s Pacira (PCRX) RSU award?

The 19,273 RSUs vest in four equal annual installments starting on February 15, 2027. Vesting occurs only if Lauren Riker remains in continuous service with Pacira on each vesting date, aligning the award with multi-year retention and performance.

What does each Pacira (PCRX) restricted stock unit granted to Lauren Riker represent?

Each restricted stock unit represents the right to receive one share of Pacira common stock in the future. Delivery occurs as the RSUs vest over four annual installments beginning February 15, 2027, subject to her continued employment with the company.

Who is the insider involved in this Pacira (PCRX) Form 4 filing and what is her role?

The insider is Lauren Riker, Senior Vice President, Finance at Pacira BioSciences, Inc. She is an officer of the company but not a director or 10% owner. The Form 4 reports her receipt of a 19,273-unit restricted stock award.